IL252612B - Calmodulin kinase kinase 1 as a novel regenerative medicine - Google Patents

Calmodulin kinase kinase 1 as a novel regenerative medicine

Info

Publication number
IL252612B
IL252612B IL252612A IL25261217A IL252612B IL 252612 B IL252612 B IL 252612B IL 252612 A IL252612 A IL 252612A IL 25261217 A IL25261217 A IL 25261217A IL 252612 B IL252612 B IL 252612B
Authority
IL
Israel
Prior art keywords
camkk1
regenerative therapeutic
novel regenerative
novel
therapeutic
Prior art date
Application number
IL252612A
Other languages
English (en)
Hebrew (he)
Other versions
IL252612A0 (en
Original Assignee
Summa Health
Northeast Ohio Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summa Health, Northeast Ohio Medical Univ filed Critical Summa Health
Publication of IL252612A0 publication Critical patent/IL252612A0/en
Publication of IL252612B publication Critical patent/IL252612B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
IL252612A 2014-12-01 2017-06-01 Calmodulin kinase kinase 1 as a novel regenerative medicine IL252612B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Publications (2)

Publication Number Publication Date
IL252612A0 IL252612A0 (en) 2017-07-31
IL252612B true IL252612B (en) 2021-07-29

Family

ID=56092307

Family Applications (2)

Application Number Title Priority Date Filing Date
IL252612A IL252612B (en) 2014-12-01 2017-06-01 Calmodulin kinase kinase 1 as a novel regenerative medicine
IL284408A IL284408B (en) 2014-12-01 2021-06-27 Calmodulin kinase kinase 1 as a novel regenerative medicine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL284408A IL284408B (en) 2014-12-01 2021-06-27 Calmodulin kinase kinase 1 as a novel regenerative medicine

Country Status (12)

Country Link
US (2) US11273208B2 (cg-RX-API-DMAC7.html)
EP (2) EP3940068A1 (cg-RX-API-DMAC7.html)
JP (2) JP6893873B2 (cg-RX-API-DMAC7.html)
KR (3) KR102236843B1 (cg-RX-API-DMAC7.html)
AU (1) AU2015355188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007055C (cg-RX-API-DMAC7.html)
CL (1) CL2017001390A1 (cg-RX-API-DMAC7.html)
CR (1) CR20170301A (cg-RX-API-DMAC7.html)
IL (2) IL252612B (cg-RX-API-DMAC7.html)
RU (1) RU2017122817A (cg-RX-API-DMAC7.html)
UA (1) UA124450C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016089826A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089826A1 (en) 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
EP3781182A4 (en) 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002072115A2 (en) 2001-03-09 2002-09-19 Board Of Regents, The University Of Texas System Vectors, compositions and methods for treating a vascular disorder
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
CN101103101B (zh) 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US20090246179A1 (en) 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2016089826A1 (en) * 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法

Also Published As

Publication number Publication date
JP2021098717A (ja) 2021-07-01
EP3227441B1 (en) 2021-06-30
WO2016089826A1 (en) 2016-06-09
EP3227441A1 (en) 2017-10-11
US20170340712A1 (en) 2017-11-30
KR20210010662A (ko) 2021-01-27
CA3007055A1 (en) 2016-06-09
CA3007055C (en) 2023-08-01
UA124450C2 (uk) 2021-09-22
KR102460983B1 (ko) 2022-10-31
JP6893873B2 (ja) 2021-06-23
KR102236843B1 (ko) 2021-04-07
CR20170301A (es) 2018-02-01
EP3940068A1 (en) 2022-01-19
US11273208B2 (en) 2022-03-15
KR20220151004A (ko) 2022-11-11
AU2015355188A1 (en) 2017-07-20
RU2017122817A3 (cg-RX-API-DMAC7.html) 2019-06-11
AU2015355188B2 (en) 2021-08-26
KR20170088988A (ko) 2017-08-02
BR112017011490A2 (pt) 2018-02-27
JP2018502838A (ja) 2018-02-01
CL2017001390A1 (es) 2018-05-11
RU2017122817A (ru) 2019-01-10
IL284408B (en) 2022-06-01
KR102610068B1 (ko) 2023-12-06
US20220233653A1 (en) 2022-07-28
IL252612A0 (en) 2017-07-31
EP3227441A4 (en) 2018-08-15
IL284408A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
HUE051354T2 (hu) Terapeutikum
GB201415569D0 (en) Therapeutic Compounds
GB201410216D0 (en) Therapeutic
GB201421287D0 (en) A pack
GB201418281D0 (en) A pack
GB201604376D0 (en) Improvements to a propellar
IL284408B (en) Calmodulin kinase kinase 1 as a novel regenerative medicine
GB201510637D0 (en) Therapeutic
GB201416273D0 (en) Therapeutic compounds
GB201416345D0 (en) A pack
GB201409666D0 (en) A bat
GB2531773B (en) Medicine pack
GB201414542D0 (en) Novel therapy
GB201410334D0 (en) Therapeutic
AU2014117V (en) Calkwr Callistemon hybrid
AU5490P (en) WES08 Westringia hybrid
GB201418508D0 (en) Therapeutic
AU2014904307A0 (en) A Therapeutic Composition
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201406674D0 (en) Therapeutic
GB201409405D0 (en) Therapeutic compounds
GB201407122D0 (en) Therapeutic compounds
GB201406748D0 (en) Therapeutic compounds
GB201415466D0 (en) A new approach to trackbed construction